tiprankstipranks
Livzon Pharmaceutical Group Inc Class H (HK:1513)
HKEX:1513

Livzon Pharmaceutical Group (1513) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1513 Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Livzon
Pharmaceutical Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1513 Stock 12 Months Forecast

Average Price Target

HK$34.97
▲(28.08% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Livzon Pharmaceutical Group in the last 3 months. The average price target is HK$34.97 with a high forecast of HK$35.00 and a low forecast of HK$35.00. The average price target represents a 28.08% change from the last price of HK$27.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"HK$22","29":"HK$29","36":"HK$36","25.5":"HK$25.5","32.5":"HK$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.002034862151,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.96659735,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$34.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.002034862151,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,25.5,29,32.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.55,24.430925758627,25.311851517254002,26.192777275881,27.073703034508,27.954628793135,28.835554551762,29.716480310389002,30.597406069016,31.478331827643,32.359257586270004,33.240183344897,34.121109103524,{"y":35.002034862151,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.55,24.428199796153848,25.30639959230769,26.18459938846154,27.062799184615386,27.94099898076923,28.819198776923077,29.697398573076924,30.575598369230768,31.453798165384615,32.33199796153846,33.210197757692306,34.08839755384615,{"y":34.96659735,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.55,24.430925758627,25.311851517254002,26.192777275881,27.073703034508,27.954628793135,28.835554551762,29.716480310389002,30.597406069016,31.478331827643,32.359257586270004,33.240183344897,34.121109103524,{"y":35.002034862151,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.809,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.949,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.87,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.418,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.247,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.8,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.85,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.15,"date":1694131200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.95,"date":1696550400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.05,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.7,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.55,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$35.00Average Price TargetHK$34.97Lowest Price TargetHK$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
HK$35.20
Buy
28.94%
Upside
Reiterated
10/27/23
Livzon Pharmaceutical Group Inc. (1513:HK) (LVZPF) PT Lowered to HK$35.20 at CitiCiti analyst Cui Cui lowered the price target on Livzon Pharmaceutical Group Inc. (1513:HK) (OTC: LVZPF) to HK$35.20 (from HK$36.60) while maintaining a Buy rating.
Morgan Stanley
HK$20.00
Sell
-26.74%
Downside
Reiterated
09/08/23
Livzon Pharmaceutical Group Inc. (1513:HK) (LVZPF) PT Lowered to HK$20 at Morgan StanleyMorgan Stanley analyst Sean Wu lowered the price target on Livzon Pharmaceutical Group Inc. (1513:HK) (OTC: LVZPF) to HK$20.00 (from HK$21.60) while maintaining a Underweight rating.

Best Analysts Covering Livzon Pharmaceutical Group

Which Analyst Should I Follow If I Want to Buy HK:1513 and Sell After:
1 Month
Success Rate
1/2 ratings generated profit
50%
Average Return
+1.35%
reiterated a buy rating 4 months ago
Copying Cui Cui's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.35% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Sean Wu CFAMorgan Stanley
Success Rate
2/3 ratings generated profit
67%
Average Return
+3.43%
reiterated a sell rating 6 months ago
Copying Sean Wu CFA's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.43% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Sean Wu CFAMorgan Stanley
Success Rate
2/3 ratings generated profit
67%
Average Return
+0.47%
reiterated a sell rating 6 months ago
Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +0.47% per trade.
2 Years
Sean Wu CFAMorgan Stanley
Success Rate
2/3 ratings generated profit
67%
Average Return
+1.03%
reiterated a sell rating 6 months ago
Copying Sean Wu CFA's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +1.03% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1513 Analyst Recommendation Trends

Rating
Dec 21
Sep 22
Sep 23
Oct 23
Jan 24
Strong Buy
2
1
0
1
2
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
1
2
3
2
1
Strong Sell
0
0
0
0
0
total
3
3
3
3
3
In the current month, 1513 has received 2 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. 1513 average Analyst price target in the past 3 months is HK$34.97.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1513 Financial Forecast

1513 Earnings Forecast

Next quarter’s earnings estimate for 1513 is HK$0.47 with a range of HK$0.36 to HK$0.57. The previous quarter’s EPS was HK$0.54. 1513 beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.71% of the time in the same period. In the last calendar year 1513 has Underperformed its overall industry.
Next quarter’s earnings estimate for 1513 is HK$0.47 with a range of HK$0.36 to HK$0.57. The previous quarter’s EPS was HK$0.54. 1513 beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.71% of the time in the same period. In the last calendar year 1513 has Underperformed its overall industry.

1513 Sales Forecast

Next quarter’s sales forecast for 1513 is HK$3.25B with a range of HK$3.25B to HK$3.25B. The previous quarter’s sales results were HK$3.16B. 1513 beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 56.95% of the time in the same period. In the last calendar year 1513 has Underperformed its overall industry.
Next quarter’s sales forecast for 1513 is HK$3.25B with a range of HK$3.25B to HK$3.25B. The previous quarter’s sales results were HK$3.16B. 1513 beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 56.95% of the time in the same period. In the last calendar year 1513 has Underperformed its overall industry.

1513 Stock Forecast FAQ

What is HK:1513’s average 12-month price target, according to analysts?
Based on analyst ratings, Livzon Pharmaceutical Group Inc Class H’s 12-month average price target is HK$34.97.
    What is HK:1513’s upside potential, based on the analysts’ average price target?
    Livzon Pharmaceutical Group Inc Class H has 28.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Livzon Pharmaceutical Group Inc Class H a Buy, Sell or Hold?
          Livzon Pharmaceutical Group Inc Class H has a conensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Livzon Pharmaceutical Group Inc Class H’s share price target?
            The average share price target for Livzon Pharmaceutical Group Inc Class H is HK$34.97. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$35.00 ,and the lowest forecast is HK$35.00. The average share price target represents 28.08% Increase from the current price of HK$27.3.
              What do analysts say about Livzon Pharmaceutical Group Inc Class H?
              Livzon Pharmaceutical Group Inc Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Livzon Pharmaceutical Group Inc Class H?
                To buy shares of HK:1513, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis